| CIMB | OCBC |
|
Mapletree Industrial Trust Growing momentum in hi-tech buildings
■ We have done a comprehensive review of MINT and its forecasts. We raise our FY17F DPU by 1.7% but cut our FY18-19F by 3.7-6.4%. ■ Underpinned by the two development projects, MINT offers one of the highest DPU growth rates in our S-REIT coverage. ■ In the medium term, MINT could expand overseas or make bolt-on data centre acquisitions in the US or European markets. ■ We expect flatted factories’ rents to hold up and hi-tech buildings’ occupancy to rise sharply. Fiercest near-term pressures will be on business parks. ■ Attractive entry point emerging; reiterate Add with MINT still one of our top picks.
|
Raffles Medical Group: Upgrade after price correction Slow but steady earnings growth Expansion plans on track Current price point attractive
We note that Raffles Medical Group (RMG)’s share price has corrected by another ~8% since the release of its 3Q16 results in late Oct. Given the on-going expansion plans, expenses may inevitably run ahead of topline contribution, thus a slower earnings growth trajectory vs. earlier years. Nonetheless in the longer run, growth remains intact in our view. In addition to a steady long term growth story, RMG also has a healthy balance sheet with net cash of S$78.0m as of 30 Sep-16. At current price point, we are upgrading RMG from hold to BUY, with an unchanged fair value estimate of S$1.61, offering a potential total return of ~17%.
|
| PHILLIP SECURITIES | |
|
Centurion Corporation Limited Oversold and underrated SINGAPORE | REAL ESTATE | INITIATION Singapore’s 2 nd largest Purpose-Built Workers’ Accommodation operator by number of beds and the only Purpose-Built Workers’ Accommodation provider in Malaysia Exposure to rising demand of mobile student population in UK and Australia Initiate with “Buy” rating with S$0.42 TP, implying an upside 37.53% (including dividends).
|
|
| DBS VICKERS | UOB KayHian |
|
Genting Singapore Double up Potential doubling of dividend to trigger further re-rating. We maintain our BUY call on Genting Singapore (GENS) with a revised TP of S$1.15. Based on our analysis of GENS's cashflow generation and net cash of c.S$3.7bn, balanced against the redemption of its perpetual securities and potential bid for a Japanese casino, we estimate that GENS has the ability to increase its dividend to 6 Scts per annum up (translating to a 6.3% yield) from our FY15F DPS 3 Scts. We believe the positive market response following the declaration of a 1.5-Sct interim dividend will encourage GENS’s management to return more cash back to its shareholders. This in turn should continue the rerating post the 3Q16 results.
|
ComfortDelGro Corporation (CD SP) Strengths On Many Fronts Except Share Price Despite resilient 3Q16 results, CD trades at an undemanding 15x 2017F PE, 9% below its 10-year historical PE average. We believe the discount is not justified, given CD’s strong fundamentals and cash generation capability. There is dividend payout upside on its transition to an asset-light model as well as M&A opportunities, which are potential share price catalysts. Maintain BUY and PE-based target price of S$2.90 (unchanged).
|
Check out our compilation of Target Prices
